1 Study Matches
Site for A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) in subjects with IgA nephropathy
This study will evaluate the safety and effectiveness of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy.
Participation for 27 weeks. visits weekly to receive study medication until week 23, visits every 4 weeks to also include blood and urine collection.
up to $100.00 per visit
Kim Hitz - at email@example.com or 717-531-4924
18 year(s) or older
Inclusion Criteria:diagnosis of IgA nephropathy confirmed by biopsy
≥ 18 years old and ≤ 70 years old
Able and willing to complete all study visits and tests
Woman of childbearing potential agreeable to use an effective form of birth control
Exclusion Criteria:History of kidney or other organ transplant
received systemic glucocorticoids or immunosuppressive therapy in previous 3 months
previous or current diagnosis of active tuberculosis
malignant tumor within 10 years
Kidney & Urinary System